MASTERINVEST Kapitalanlage GmbH bought a new position in Becton, Dickinson and Company (NYSE:BDX - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 10,272 shares of the medical instruments supplier's stock, valued at approximately $1,554,000.
Other hedge funds have also modified their holdings of the company. Parvin Asset Management LLC bought a new position in shares of Becton, Dickinson and Company during the 2nd quarter worth approximately $644,000. Stonebridge Capital Management Inc. purchased a new stake in Becton, Dickinson and Company during the second quarter valued at approximately $711,000. Pure Financial Advisors LLC acquired a new stake in Becton, Dickinson and Company in the second quarter valued at approximately $240,000. Transamerica Financial Advisors LLC purchased a new position in Becton, Dickinson and Company in the second quarter worth $215,000. Finally, Corient Private Wealth LP purchased a new position in Becton, Dickinson and Company in the second quarter worth $11,326,000. 86.97% of the stock is owned by hedge funds and other institutional investors.
Becton, Dickinson and Company Stock Performance
BDX opened at $188.11 on Friday. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $193.07. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $51.83 billion, a PE ratio of 56.66, a P/E/G ratio of 13.41 and a beta of 0.19. The firm has a 50 day moving average of $165.23 and a two-hundred day moving average of $160.33.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm's revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the company earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current year.
Becton, Dickinson and Company Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be paid a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company's payout ratio is currently 126.51%.
Analyst Upgrades and Downgrades
BDX has been the subject of several analyst reports. Jefferies Financial Group reiterated a "buy" rating and set a $210.00 price objective on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. TD Cowen upped their target price on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a "hold" rating in a research report on Wednesday, August 5th. Bank of America decreased their price target on Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. Royal Bank Of Canada raised their price target on Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a "sector perform" rating in a report on Thursday, August 13th. Finally, Evercore set a $180.00 price target on Becton, Dickinson and Company in a research note on Monday, July 6th. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $185.67.
Check Out Our Latest Stock Report on Becton, Dickinson and Company
Insider Activity
In related news, EVP Roland Goette sold 2,438 shares of the firm's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the sale, the executive vice president owned 14,856 shares in the company, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 1,100 shares of the firm's stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the sale, the executive vice president owned 13,172 shares in the company, valued at $1,918,633.52. This trade represents a 7.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 11,869 shares of company stock valued at $1,994,719. 0.40% of the stock is currently owned by corporate insiders.
Becton, Dickinson and Company Profile
(
Free Report)
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
